HDAC1 and HDAC2 (ranked at 3 and 4), among class I HDACs, were reported to regulate the changes in histone acetylation and were associated with HDAC inhibitors that were expected to reverse hypoacetylation levels observed even at the early stages of breast cancer progression [29]. This evidence concerns the gene HDAC9 and breast cancer.